26 C
Vientiane
Tuesday, June 17, 2025
spot_img
Home Blog Page 501

AIM’s Serum-Free Iterative Rabies Vaccine Receives Acceptance for Market Registration; Institutions Predict Significant Valuation Recovery Potential for the Company

HONG KONG, April 8, 2025 /PRNewswire/ — AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced on April 7, 2025 that the company’s research and development of the serum-free iterative rabies vaccine has received an “Acceptance Notice” from the National Medical Products Administration for market registration. In addition, the vaccine has obtained the corresponding product production license. Currently, there are no serum-free rabies vaccines approved for sale in the global market, and this product is expected to become the first of its kind to launch.

AIM Vaccine is rapidly advancing the market launch process for its iterative major vaccine products, confirming the optimistic forecasts made by investors. As noted in a research report published by Fosun International Securities on April 3, the operational improvements at AIM Vaccine have been validated, its innovative pipeline is ready to launch, and there is significant potential for valuation recovery. With the upcoming launches of three major new products, including the serum-free iterative rabies vaccine in the next 1-2 years, the company’s revenue is expected to accelerate, and profitability is projected to improve significantly, potentially achieving breakeven and quickly entering a profit period after 2025. The target price for the company is maintained at HKD 11.22, with a “Buy” rating.

According to the research report from Fosun International Securities, AIM’s serum-free rabies vaccine well represents the direction of technological upgrades in rabies vaccines. The production process does not use animal serum, significantly increasing safety and reducing allergy risks, with excellent efficacy and safety indicators shown in Phase III clinical trial results.

The serum-free iterative rabies vaccine is recognized as a high-value product in the industry. The report from Fosun International Securities points out that, based on solidifying its market share in Vero cell vaccines, AIM’s serum-free iterative rabies vaccine and its iterative high-yield diploid cell (HDC) vaccine represent significant technological upgrades and value enhancement capabilities. The HDC vaccine is priced significantly higher than the current Vero cell vaccine, which still holds 95% of the market share, while the serum-free vaccine, with its higher safety profile, is expected to further surpass the pricing of the HDC vaccine.

PRC is the largest rabies vaccine market globally. According to statistics from Frost & Sullivan, driven by product upgrades and increasing rabies vaccine awareness, it is expected to reach RMB 14.8 billion by 2030. According to the “National Regulation for the Rabies Exposure Prophylaxis (2023 Edition)” established by the National Disease Control and Prevention Administration (NDCPA) and the National Health Commission of PRC(NHC), rabies vaccination clinics are required to provide at least two different types of rabies vaccines. AIM’s serum-free rabies vaccine, with its technological advantages, is expected to become the first choice for vaccination institutions.

As such, the report from Fosun International Securities believes that AIM has not only maintained its strong market share acquisition and commercialization capabilities in the mature vaccine market but has also made crucial progress in its transition to high-value vaccines.

With the gradual realization of its product line, AIM is expected to continuously improve cash flow and achieve profitability after 2025. With its rich product pipeline, leading technology platform, and forward-looking strategic layout, AIM Vaccine is set to play an increasingly important role in both the PRC and global vaccine markets.

 

PRA Group Announces Leadership Succession Plan

Martin Sjolund appointed President and Chief Executive Officer, effective June 17, 2025

Vikram Atal to serve as senior advisor through December 31, 2025

NORFOLK, Va., April 8, 2025 /PRNewswire/ — PRA Group, Inc. (Nasdaq: PRAA), a global leader in acquiring and collecting nonperforming loans, today announced that its Board of Directors has appointed President of PRA Group Europe Martin Sjolund to serve as President and Chief Executive Officer (CEO), effective June 17, 2025. Sjolund succeeds current President and CEO Vikram Atal, who announced that he will retire and serve as a senior advisor through December 31, 2025. Sjolund will be appointed to the Board upon assuming the role of President and CEO, and Atal will retire from the Board at that time.

President of PRA Group Europe Martin Sjolund appointed President and CEO of PRA Group effective June 17, 2025.
President of PRA Group Europe Martin Sjolund appointed President and CEO of PRA Group effective June 17, 2025.

“On behalf of the Board, I want to thank Vik for his leadership of PRA Group during a pivotal time,” said Executive Chair of the Board Steve Fredrickson. “Today’s announcement is the culmination of the Board’s ongoing succession planning process and commitment to enabling long-term, profitable growth.”

“It has been a privilege to lead PRA Group through this transformative time in the company’s history,” said Atal. “Since March 2023, I have worked closely with Martin, and I am highly confident in his ability to further strengthen our global leadership position. His strong track record in our European business, extensive industry knowledge, thoughtful leadership and commitment to our culture and customers will build on our strengths and create meaningful value for our shareholders in the years to come.”

“I am honored to have the opportunity to lead PRA Group as we enter our next phase of growth,” said Sjolund. “As a team, we have already achieved record global portfolio purchases and double-digit cash growth, expanded our leadership team, improved operational processes and strengthened our capital structure. These actions have positioned us to continue driving the company forward while delivering value to our shareholders.”

About Martin Sjolund
Sjolund has served as President of PRA Group Europe since 2018, providing leadership across 15 markets in Europe, Canada and Australia. During his tenure, Sjolund oversaw nearly $3 billion of successful portfolio investments across Europe, all while significantly improving the profitability of the European business. He led our expansion into two new markets, modernized the IT infrastructure and contact platforms, enhanced the data and analytics function and ultimately created one of Europe’s most cost-efficient debt buying platforms.

Before being promoted to his current role, Sjolund served as Chief Operating Officer of Europe from 2015 until 2018. He was previously Director of Group Strategy and Corporate Development (Europe), a position he also held at Aktiv Kapital from 2011 until PRA Group acquired Aktiv Kapital in 2014.

Prior to joining Aktiv Kapital, Sjolund held leadership positions in global technology companies and was a management consultant with McKinsey & Company in Singapore and London. Sjolund holds an MBA from the University of Chicago and is a graduate of Georgetown University.

About PRA Group
As a global leader in acquiring and collecting nonperforming loans, PRA Group, Inc. returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe and Australia. With thousands of employees worldwide, PRA Group companies collaborate with customers to help them resolve their debt. For more information, please visit www.pragroup.com.

News Media Contact:
Elizabeth Kersey
Senior Vice President, Communications and Public Policy
(757) 641-0558
Elizabeth.Kersey@PRAGroup.com

Investor Contact:
Najim Mostamand, CFA
Vice President, Investor Relations
(757) 431-7913
IR@PRAGroup.com

Acclime acquires The Advisory Group to strengthen service capabilities in Australasia

AUCKLAND, New Zealand, April 8, 2025 /PRNewswire/ — Acclime, a leading global provider of business advisory, tax, and governance services, is pleased to announce the acquisition of The Advisory Group (TAG), a highly regarded professional services firm based in Auckland. Founded in 2006, TAG has grown to employ over 30 professionals, specialising in tax, advisory, and company secretarial services for SMEs, multinational corporations, and high-net-worth individuals.

This strategic acquisition allows Acclime to broaden its service offerings and provide TAG’s clients with enhanced opportunities for regional and global expansion through Acclime’s extensive network across 18+ markets worldwide. TAG’s expertise will complement Acclime’s existing services in New Zealand, including business advisory, virtual CFO services, film and entertainment services, tax advisory, and fund services.

Izzy Silva, Group CEO of Acclime, commented: “We are thrilled to welcome the talented TAG team to Acclime. Their extensive experience will significantly strengthen our presence and service provision across Australasia. As Acclime continues to expand its differentiated professional services in the region, New Zealand plays a pivotal role in supporting our clients, particularly those entering the market or seeking growth opportunities in Asia. We are also excited to have Sudhir Lala, Graham Lawrence, and Martyn Henderson join the New Zealand leadership team, and we look forward to working together to drive long-term value for our clients.”

Randolph van der Burgh, Acclime’s Regional Director Australasia, added: “The acquisition of TAG boosts our advisory capabilities in Australasia and solidifies Acclime’s position as a Top 20 accounting, tax, advisory, and governance firm in New Zealand.”

Sudhir Lala, Director of The Advisory Group, shared his thoughts on the acquisition: “We have experienced strong growth in recent years, and joining Acclime represents the next logical step in our journey. This partnership offers tremendous opportunities for both our team and our clients. We are already seeing positive outcomes as we collaborate to deliver greater value to our clients.”

Acclime’s existing Auckland office in Ellerslie will continue operations alongside TAG’s downtown CBD office. TAG will rebrand under the Acclime name later this year.

About Acclime

Acclime provides businesses with corporate, governance, and advisory services. It operates in 18+ markets, employing 1,600+ dedicated professionals. The firm provides a comprehensive range of professional services and business advisory to help businesses navigate complex regulatory environments and achieve their goals at all stages of the business life cycle.

www.acclime.com

About The Advisory Group

Founded in 2006, The Advisory Group is a boutique, chartered accounting practice specialising in providing accounting, taxation, and business advice to successful privately owned businesses and to high-net-worth individuals. Based in Auckland, The Advisory Group team has the experience and the expertise to advise on complex business affairs, and welcomes close, personal and trusting relationships.

CAS and Cleveland Clinic collaborate to accelerate research through advanced AI and quantum computing

COLUMBUS, Ohio, April 8, 2025 /PRNewswire/ — CAS, a division of the American Chemical Society specializing in scientific content and knowledge management, and Cleveland Clinic, an academic health system with a global footprint, announced plans for a strategic collaboration that will unite the organizations’ unique expertise, technology, and data capabilities to fuel clinical research.

CAS and Cleveland Clinic
CAS and Cleveland Clinic

During the Cleveland Discovery & Innovation Forum, an event highlighting cutting-edge healthcare and life sciences research, the two global organizations announced that their collaboration’s first strategic focus area will be aiming to advance research on health, wellness, and healthy aging. Initial projects the organizations are discussing will focus on drug discovery for brain health, a priority underscored by the relative lack of effective, disease-modifying treatments for Alzheimer’s due to the complex nature of the disease.

“This unique collaboration leverages Cleveland Clinic’s expertise in biomedical research and clinical care with CAS leadership in scientific data and technology,” said Lara Jehi, M.D., Cleveland Clinic Chief Research Information Officer. “By combining our strengths, we aim to create high-quality medical data, validate scientific models, and integrate research to ultimately enhance patient care and chronic disease management.”

The effort will harness the CAS Content Collection™, the world’s most comprehensive curated scientific information resource, with advanced technologies, including new AI models and quantum computing. As part of its partnership with IBM, Cleveland Clinic houses an IBM Quantum System One, the world’s first quantum computer fully dedicated to healthcare research.

The collaborators plan to build and train disease-specific models, starting with Alzheimer’s, focused on advancing preventative and predictive strategies, and potentially translating them to other chronic diseases in the future.

“CAS is delighted to partner with Cleveland Clinic, an institution renowned for its exceptional research and innovation,” said Manuel Guzman, CAS President. “Recognizing it takes 17 years for a scientific discovery in a lab to become an approved test or therapy, we are confident that together, we can close that gap. Led by our shared goal of improving people’s lives through scientific innovation, we will combine high-quality content, subject expertise, and advanced technologies to discover new paths to healthy aging and drive positive social and economic impacts.”

The initiative will benefit from the Cleveland Innovation District, which brings the State of Ohio and JobsOhio together with Cleveland’s healthcare and higher education institutions to create jobs, accelerate research, and educate the future workforce.

About CAS

CAS connects the world’s scientific knowledge to accelerate breakthroughs that improve lives. We empower global innovators to efficiently navigate today’s complex data landscape and make confident decisions in each phase of the innovation journey. As a specialist in scientific knowledge management, our team builds the largest authoritative collection of human-curated scientific data in the world and provides essential information solutions, services, and expertise. Scientists, patent professionals, and business leaders across industries rely on CAS to help them uncover opportunities, mitigate risks, and unlock shared knowledge so they can get from inspiration to innovation faster. CAS is a division of the American Chemical Society.

About Cleveland Clinic  

Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. Cleveland Clinic is consistently recognized in the U.S. and throughout the world for its expertise and care. Among Cleveland Clinic’s 81,000 employees worldwide are more than 5,743 salaried physicians and researchers, and 20,160 registered nurses and advanced practice providers, representing 140 medical specialties and subspecialties. Cleveland Clinic is a 6,690-bed health system that includes a 173-acre main campus near downtown Cleveland, 23 hospitals, 276 outpatient facilities, including locations in northeast Ohio; Florida; Las Vegas, Nevada; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2023, there were 13.7 million outpatient encounters, 323,000 hospital admissions and observations, and 301,000 surgeries and procedures throughout Cleveland Clinic’s health system. Patients came for treatment from every state and 132 countries.

 

Kia Design Presents Opposites United: Eclipse of Perceptions at Milan Design Week 2025

  • Kia Design returns to Milan Design Week for third consecutive year, providing a platform for artistic expression and cultural exchange
  • Works by artists Philippe Parreno and A.A. Murakami curated to reflect the brand’s ‘Opposites United’ design philosophy
  • Marquee’, ‘The Cave’, ‘Beyond the Horizon’ and ‘The Eclipse’ deliver a sensory journey echoing the evolution of Kia’s design philosophy
  • Exhibition runs from April 7-13 at Museo della Permanente in Milan, Italy

MILAN, April 8, 2025 /PRNewswire/ — Kia Design has introduced the theme of its Milan Design Week 2025 exhibition, Opposites United: Eclipse of Perceptions, in collaboration with internationally acclaimed artists Philippe Parreno and A.A. Murakami (Azusa Murakami and Alexander Groves).

‘Marquee’ by Philippe Parreno at Kia’s ‘Opposites United: Eclipse of Perceptions’ exhibition
‘Marquee’ by Philippe Parreno at Kia’s ‘Opposites United: Eclipse of Perceptions’ exhibition

This year’s exhibition continues Kia’s commitment to cultural exchange and creative exploration. Focusing on the brand’s evolving transformation – rooted in its core cultural values and creative identity – the event sparks conversations that challenge and inspire both Kia Design and the global creative community.

By bringing together visionary artists such as Philippe Parreno and A.A. Murakami, alongside Kia Design and other prominent members of the global creative community, the exhibition aims to offer an interactive experience where visitors can engage with the ideas, philosophies, and expressions that shape contemporary creativity.

Since its first participation in Milan Design Week in 2023, Kia Design has sought to support art and culture by providing a platform for artists to express their interpretations of the brand’s design philosophy, ‘Opposites United’. Participating artists collaborate on experimental approaches, expressing the ‘Opposites United’ theme through their works or performances, creating resonant experiences for visiting audiences.

The Eclipse

A central stage for performances and talk sessions, ‘The Eclipse’ features tiered seating reminiscent of the Colosseum, with content projected onto a layered system of shades. In this space, the audience is encouraged to become active participants, immersed in the content and interpreting it subjectively, rather than simply remaining as observers.

Eclipses have held significant scientific, religious, and cultural meanings throughout human history. These celestial events have inspired us to dream, look beyond our own existence, predict the future and advance our technologies.

Opposites United: Eclipse of Perceptions uses the space to embody the story of Kia Design, and its ambition to evolve relentlessly, through dramatic staging and spatial transformations.

To read the full text, please visit the Kia Global Media Center.

‘The Cave’ by A.A. Murakami at Kia’s ‘Opposites United: Eclipse of Perceptions’ exhibition
‘The Cave’ by A.A. Murakami at Kia’s ‘Opposites United: Eclipse of Perceptions’ exhibition

BeLive Holdings Announces Closing of Approximately $10,000,000 Initial Public Offering

SINGAPORE, April 8, 2025 /PRNewswire/ — BeLive Holdings (the “Company” or “BeLive”), a provider of live commerce and shoppable short videos solutions (“BeLive Solutions”) to international retail companies and e-commerce marketplaces, today announced the closing of its initial public offering (the “Offering”) of 2,450,000 ordinary shares (the “Ordinary Shares”) at a public offering price of US$4.00 per share for total gross proceeds of US$9.8 million, before deducting underwriting discounts and other offering expenses. The Offering closed on April 7, 2025 and the Ordinary Shares began trading on Nasdaq Capital Market on April 4, 2025, under the ticker symbol “BLIV”.


The Company has granted the underwriters an option, within 45 days from the date of the prospectus, to purchase up to an additional 367,500 Ordinary Shares at the public offering price, less underwriting discounts, to cover the over-allotment option, if any.

The Company intends to use the proceeds from this Offering for (i) advancing its video and live streaming technologies, artificial intelligence (“AI”) and big data capabilities; (ii) solution development to expand and enhance its current solution offerings, as well as to develop new features and functionalities to continue to provide innovative value propositions to its customers; (iii) marketing and branding, including marketing and promotional activities to further expand its customer base and strengthen its brand; and (iv) general corporate purposes that are beneficial in developing the business and its strategic direction.

R.F. Lafferty & Co., Inc. (“R.F. Lafferty”), acted as sole book-running manager for the Offering. Schlueter & Associates, P.C. acted as U.S. counsel to the Company, and Lucosky Brookman LLP acted as U.S. counsel to R.F. Lafferty, in connection with the Offering.

A registration statement on Form F-1 (File No. 333-280739) relating to the Offering, as amended, has been filed with the U.S. Securities and Exchange Commission (the “SEC”) and was declared effective by the SEC on March 31, 2025. The Offering was made only by means of a prospectus. Copies of the final prospectus related to the Offering may be obtained, from R.F. Lafferty, Attn: offerings@rflafferty.com or via standard mail to R. F. Lafferty & Co., Inc., 40 Wall Street, 27th Floor, New York, NY 10005. In addition, a copy of the final prospectus can also be obtained via the SEC’s website at www.sec.gov.

Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About BeLive Holdings Limited

Headquartered in Singapore, BeLive provides live commerce and shoppable short videos solutions (“BeLive Solutions”) to international retail companies and e-commerce marketplaces. Our BeLive Solutions enable our customers to leverage the power of interactive and immersive live and video commerce to their online business and enable our customers to curate unique videos that may also be aired real-time as they are simultaneously being recorded, for anytime instant replay. We categorize our BeLive Solutions into (i) an enterprise-grade BeLive White Label Solution which is customized to meet a customer’s unique requirements, and which can be integrated into their existing internal system and (ii) a cloud-based software-as-a-service (SaaS) solution (“BeLive SaaS Solution”) for customers who are looking for a quick and cost-effective live commerce and shoppable short video solution without the necessity of building their own infrastructure and technology stack. For more information, please visit: http://www.belive.technology

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, the Company’s statements regarding the expected trading of its Ordinary Shares on the Nasdaq Capital Market and the closing of the Offering. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and the completion of the initial public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Investor Relations
ir@belive.sg 

Canada Leads: Canada’s No. 1 Hospital Announces Strategy to Attract World’s Most Promising Scientists, Drive Health Innovation and Economic Growth

TORONTO, April 8, 2025 /PRNewswire/ — In a bold move to position Canada as the ultimate destination for the brightest minds in medical research, whose work will help build our future economy, University Health Network (UHN) is unveiling the ambitious Canada Leads 100 Challenge to recruit 100 world-leading early-career scientists to Canada’s No. 1 hospital. As part of the strategy, UHN will focus on the recruitment of scientists whose research has the potential to fuel economic development, Canadian-based manufacturing and high-quality jobs.

To ignite this transformational opportunity, UHN, with the support of UHN Foundation, has already secured an initial investment of $15 million to recruit the first 50 scientists. As part of the challenge, UHN Foundation and The Princess Margaret Cancer Foundation will now work to secure the matching investment to reach the goal of 100 new recruits.

“Attracting and retaining the best scientists and entrepreneurs is critical to the future economic growth of Ontario and Canada,” said Mr. Dean Connor, Chair of the UHN Board of Trustees. “Canada Leads is designed to accelerate the rapid development of a powerful science-based economy that will translate into world-leading discoveries, protect Canada’s universal health system and create exponential economic spin-off in manufacturing, biotech and commercialization.”

Along with a two-year research funding commitment, Canada Leads awardees at UHN will also benefit from coaching and mentorship by leading entrepreneurs. UHN will also be introducing a Global Mobility Expert to their team to help support the seamless transition of the new scientists to Canada.

“I’m thrilled to see UHN launch the Canada Leads 100 Challenge that will attract the best and brightest scientists to Ontario from around the world,” said Ontario Premier Doug Ford, who was on hand for the announcement. “Initiatives like these complement Ontario’s significant investments in health care and our life sciences sector to drive Ontario’s cutting-edge medical research that improves the lives of all Ontarians, creates high-quality jobs and strengthens our economy. Congratulations to UHN on this remarkable endeavour – it’s a win for our province and a brighter future for everyone.”

Dr. Kevin Smith, President & CEO of UHN, said the circumstances are right for this initiative.

“The time is now. The opportunity is now,” Dr. Smith said. “Canadian-born discoveries can be commercialized here at home and that means our patients benefit first. It also offers the promise of a made-in-Canada supply chain of advanced medical products and services for use at home and globally.”

Sylvia Jones, Ontario’s Deputy Premier and Minister of Health, and Nolan Quinn, Ontario’s Minister of Colleges, Universities, Research Excellence & Security, were also on hand for the announcement.

“Our government is taking bold action, while making record investments in our health care system, to champion Ontario as a world leader in health care innovation, research, and delivery,” Minister Jones said. “Today’s announcement by UHN works hand-in-hand with the progress our government has achieved, through our Life Science Strategy and by breaking down barriers for health care professionals, to deliver more connected and convenient care, for generations to come.”

Minister Quinn added: “Ontario is a world-renowned destination for performing groundbreaking health care research that drives our economy and improves millions of lives. Our government is proud to foster a strong, secure, and prosperous research environment that will only be strengthened by the brilliant minds UHN’s Canada Leads 100 Challenge brings to our province.”

Dr. Brad Wouters, UHN’s Executive Vice President of Science & Research, said: “We know that there are many efforts happening across Canada that reflect a collective ambition for Canada to become a global leader in medical research, discovery and commercialization. Our aspiration is to see this replicated across Canada to ultimately recruit 1,000 early-career scientists. In the spirit of Canada Leads, we’re acting now and seizing this moment of opportunity. We call on all sectors to help us realize this ambition and welcome others to join us.”

Realizing a true transformation to a science-powered economy requires federal, provincial and municipal governments to make unprecedented investments and policy changes that position Canada as the destination for top talent. UHN looks forward to working with the next Government of Canada following the current election campaign.

“Canada Leads represents a bold and urgent call to action — an investment in talent, discovery and a healthier, more prosperous future,” said Ms. Julie Quenneville, CEO of UHN Foundation. “At UHN Foundation, we are proud to help ignite this vision by supporting the world’s most promising scientists to Canada’s No. 1 hospital, ensuring that breakthrough ideas take root and flourish right here at home. We thank the founding donors for their leadership to create a $30-million fund. “

For more information, visit: UHNCanadaLeads.ca

About University Health Network (UHN)

UHN is Canada’s No. 1 hospital and the world’s No. 1 publicly funded hospital. With 10 sites and more than 44,000 TeamUHN members. UHN consists of Toronto General Hospital, Toronto Western Hospital, Princess Margaret Cancer Centre, Toronto Rehabilitation Institute, The Michener Institute of Education and West Park Healthcare Centre. As Canada’s top research hospital, the scope of biomedical research and complexity of cases at UHN have made it a national and international source for discovery, education, and patient care. UHN has the largest hospital-based research program in Canada, with major research in neurosciences, cardiology, transplantation, oncology, surgical innovation, infectious diseases, genomic medicine and rehabilitation medicine. UHN is a research hospital affiliated with the University of Toronto. www.uhn.ca

Media Contact: Ana Fernandes, Manager, External Communications, University Health Network, M: 437-216-4597, ana.fernandes@uhn.ca 

 

Bosch establishes company with the synthetic diamond solutions provider Element Six

Quantum sensors: Partnership to extend innovation leadership

Element Six and the technology company Bosch are significantly expanding their development collaboration, which has been in place since 2023, and are establishing a joint venture, to be known as Bosch Quantum Sensing. Bosch has published this press release.

  • Bosch chairman Stefan Hartung: “Quantum sensors are a future technology with huge potential. They will improve people’s lives.”
  • By partnering with Element Six, Bosch will further extend its technological lead.
  • Synthetic diamonds are a key component of Bosch quantum sensors.
  • In the long run, Bosch estimates that the global market potential for medicine and mobility will be in the mid-single-digit billion range.
  • Bosch has been researching in the quantum technology field for more than ten years, and is investing in the commercialization of its R&D.

STUTTGART, Germany, April 7, 2025 /PRNewswire/ — They cannot be grasped, either literally or figuratively. Yet their potential is revolutionary, and they are a key technology of the future. We are talking about quanta. For more than ten years, Bosch has been researching in this field, and it is playing a decisive part in commercializing quantum sensors. Since 2023, it has had a development collaboration with Element Six, the world’s leading solutions provider of synthetic diamonds. Bosch is now significantly extending this alliance and establishing a joint venture, to be known as Bosch Quantum Sensing. The joint venture will be based on the in-house start-up of the same name, which Bosch set up in 2022. Domiciled in Ludwigsburg, Germany, Bosch Quantum Sensing currently employs 30 associates. Bosch itself will be the lead partner and be responsible for operations. Element Six will hold a 25 percent stake. It has been agreed that further financial details will not be disclosed. The establishment of the new company is still subject to official approval.

Quantum sensors from Bosch achieve unprecedented precision. Synthetic diamonds are a key component of these sensors. Source:Bosch
Quantum sensors from Bosch achieve unprecedented precision. Synthetic diamonds are a key component of these sensors. Source:Bosch

Bosch Quantum Sensing sees many areas in which novel quantum sensors can be used, from exploration of natural resources to aircraft navigation and medical technology. By the middle of the next decade, Bosch estimates that the global market potential of medical and mobility applications will be in the mid-single-digit billion euros range per year. Synthetic diamonds are a key component of Bosch quantum sensors. In stepping up its partnership with Element Six, Bosch is making a determined move toward the commercialization of quantum sensors. “Quantum sensors are a future technology with huge potential. They will bring about fundamental changes in many sectors of our economy, and improve people’s lives. In setting up this new company, we are underscoring this technology’s strategic significance for Bosch. As innovation leader of commercial quantum sensors, we will work with Element Six to further extend our technological lead,” says Stefan Hartung, chairman of the board of management of Robert Bosch GmbH.

Quantum leap toward commercialization

The distinctive qualities of these special-purpose synthetic diamonds allow quantum sensors based on them to detect even the tiniest magnetic fields. In this way, they satisfy the most exacting market requirements and make real innovations possible. “We want to work with Element Six to make quantum sensors economical and allow them to be produced on an industrial scale. In this way, we will create the basis for innovative applications that set new standards for precision and efficiency,” says Katrin Kobe, CEO of Bosch Quantum Sensing. “Through the new joint venture between Bosch and Element Six, which aligns with Element Six’ contribution towards De Beers Group’s Origins strategy, we will integrate our synthetic diamond technology with Bosch Quantum Sensing’s capabilities, unlocking new possibilities in critical sectors such as healthcare and navigation. Together, we will harness the respective decades of excellence and innovation to push the limits of what’s possible, heralding a new era of synthetic diamond-enabled technologies”, says Siobhán Duffy, the CEO of Element Six. The synthetic diamond solutions provider is in a unique position to supply the highly engineered synthetic diamonds in the quantity and quality required for industrial applications, while Bosch will integrate them into robust and scalable sensor systems. It is a classic win-win situation.

Even now, the latest Bosch quantum sensor prototype is the most compact of its kind for the level of sensitivity required – it is the same size as a modern smartphone. In the area of mobility, it could enable a robust navigation in the future, complementary to conventional GPS systems. It could also offer decisive advantages for the exploration of natural resources and, in medical technology, for the measurement of cardiac activity. The advantage of compact sensors is their portability, less expensive production, and better scalability. The long-term goal of Bosch Quantum Sensing is to make quantum sensors so small that they can be integrated onto a chip.

Press photos and infocharts are available on the Bosch Media Service at www.bosch-press.com.

Contact person for press inquiries:
Athanassios Kaliudis,
Phone: +49 711 811-7497

The Bosch Group is a leading global supplier of technology and services. It employs roughly 417,900 associates worldwide (as of December 31, 2024). According to preliminary figures, the company generated sales of 90.5 billion euros in 2024. Its operations are divided into four business sectors: Mobility, Industrial Technology, Consumer Goods, and Energy and Building Technology. With its business activities, the company aims to use technology to help shape universal trends such as automation, electrification, digitalization, connectivity, and an orientation to sustainability. In this context, Bosch’s broad diversification across regions and industries strengthens its innovativeness and robustness. Bosch uses its proven expertise in sensor technology, software, and services to offer customers cross-domain solutions from a single source. It also applies its expertise in connectivity and artificial intelligence in order to develop and manufacture user-friendly, sustainable products. With technology that is “Invented for life,” Bosch wants to help improve quality of life and conserve natural resources. The Bosch Group comprises Robert Bosch GmbH and its roughly 470 subsidiary and regional companies in over 60 countries. Including sales and service partners, Bosch’s global manufacturing, engineering, and sales network covers nearly every country in the world. Bosch’s innovative strength is key to the company’s further development. At 136 locations across the globe, Bosch employs some 86,900 associates in research and development, of which nearly 48,000 are software engineers.

The company was set up in Stuttgart in 1886 by Robert Bosch (1861–1942) as “Workshop for Precision Mechanics and Electrical Engineering.” The special ownership structure of Robert Bosch GmbH guarantees the entrepreneurial freedom of the Bosch Group, making it possible for the company to plan over the long term and to undertake significant upfront investments in the safeguarding of its future. Ninety-four percent of the share capital of Robert Bosch GmbH is held by Robert Bosch Stiftung GmbH, a charitable foundation. The remaining shares are held by Robert Bosch GmbH and by a corporation owned by the Bosch family. The majority of voting rights are held by Robert Bosch Industrietreuhand KG. It is entrusted with the task of safeguarding the company’s long-term existence and in particular its financial independence – in line with the mission handed down in the will of the company’s founder, Robert Bosch.

Additional information is available online at www.bosch.com, www.iot.bosch.com, www.bosch-press.com.

Siobhán Duffy, CEO of Element Six, and Katrin Kobe, CEO of Bosch Quantum Sensing, establishing the joint venture Bosch Quantum Sensing. Source: Bosch
Siobhán Duffy, CEO of Element Six, and Katrin Kobe, CEO of Bosch Quantum Sensing, establishing the joint venture Bosch Quantum Sensing. Source: Bosch